MXCT – maxcyte, inc. (US:NASDAQ)
Stock Stats
News
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price [Seeking Alpha]
MaxCyte, Inc. (NASDAQ: MXCT) was given a new $6.00 price target on by analysts at BTIG Research. They now have a "buy" rating on the stock.
MaxCyte, Inc. (NASDAQ: MXCT) had its price target lowered by analysts at Stifel Nicolaus from $11.00 to $9.00. They now have a "buy" rating on the stock.
MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript [Seeking Alpha]
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance [Yahoo! Finance]
Form 4 MAXCYTE, INC. For: Mar 18 Filed by: Soleymannezhad Ali
Form 4 MAXCYTE, INC. For: Mar 18 Filed by: Sandoval David I.
Form 4 MAXCYTE, INC. For: Mar 18 Filed by: Swirsky Douglas J
Form 4 MAXCYTE, INC. For: Mar 14 Filed by: Soleymannezhad Ali
Form 4 MAXCYTE, INC. For: Mar 14 Filed by: Sandoval David I.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.